85684-61-3

Usage

Uses

Used in Pharmaceutical Industry:
3-(Difluoromethoxy)benzaldehyde is utilized as a key intermediate in the synthesis of pharmaceuticals due to its ability to enhance the properties of the final drug products. Its unique structure allows for the development of new medications with improved efficacy and selectivity.
Used in Agrochemical Industry:
In the agrochemical sector, 3-(Difluoromethoxy)benzaldehyde serves as a building block for the creation of novel agrochemicals, potentially leading to more effective and environmentally friendly pesticides and other agricultural products.
Used in Organic Synthesis:
3-(Difluoromethoxy)benzaldehyde is employed as a valuable intermediate in organic synthesis, contributing to the development of a wide range of specialty chemicals that have diverse applications across various industries.
Used in Fluorinated Organic Compounds Synthesis:
3-(Difluoromethoxy)benzaldehyde is also used as a building block in the synthesis of fluorinated organic compounds, which are important in various chemical and pharmaceutical applications due to the unique properties that fluorine confers to organic molecules.
Used as a Reagent in Chemical Reactions:
3-(Difluoromethoxy)benzaldehyde functions as a reagent in a variety of chemical reactions, facilitating the formation of desired products and aiding in the advancement of chemical research and development.

InChI:InChI=1/C8H6F2O2/c9-8(10)12-7-3-1-2-6(4-7)5-11/h1-5,8H

Upstream product

• 100-83-4 meta-hydroxybenzaldehyde 
• 1895-39-2 sodium chlorodifluoroacetate 
• 188554-13-4 2-hydroxypyridine-4-carboxaldehyde 
• 620-24-6 3-Hydroxybenzyl alcohol 
• 125903-81-3 (3-(difluoromethoxy)phenyl)methanol 

Downstream Products

• 1177251-56-7 1-{(1-benzyl-1H-tetrazol-5-yl)[3-(difluoromethoxy)phenyl]methyl}-4-cyclobutyl-1,4-diazepane 
• 1268516-11-5 (2-(difluoromethoxy)pyridin-4-yl)methanol 
• 1622219-88-8 (3-(difluoromethoxy)phenyl)(2-(3,5-difluorophenyl)-1,3-dithian-2-yl)methanol 
• 1622219-89-9 2-(3-(difluoromethoxy)phenyl)-1-(3,5-difluorophenyl)-2-hydroxyethanone 
• 1622219-90-2 1-(3-(difluoromethoxy)phenyl)-2-(3,5-difluorophenyl)ethane-1,2-dione 
• 1622219-58-2 2-amino-4-(3-(difluoromethoxy)phenyl)-4-(3,5-difluorophenyl)-1-methyl-1H-imidazol-5(4H)-one 
• 97603-92-4 3-Difluoromethoxy-benzaldehyde oxime 
• 910034-86-5 1-(difluoromethoxy)-3-vinylbenzene 

Relevant academic research and scientific papers

Difluoromethylation of Phenols and Thiophenols with the S-(Difluo-romethyl)sulfonium Salt: Reaction, Scope, and Mechanistic Study

A facile and practical approach for the difluoromethylation of phenols and thiophenols was described. Making use of the recently developed bench-stable S-(difluoromethyl)sulfonium salt as the difluorocarbene precursor, a wide variety of diversely functionalized phenols and thiophenols were readily converted to their corresponding aryl difluoromethyl ethers in good to excellent yields in the presence of lithium hydroxide. Chemoselectivity of various O,S-nucleophiles toward difluorocarbene was systematically studied, suggesting the reactivity order ArS- > RS-, ArO- > ROH > RO-, ArSH, ArOH, RSH.

HYDANTOINS THAT MODULATE BACE-MEDIATED APP PROCESSING

In certain embodiments hydantoin compounds are provided herein that are effective to inhibit BACE activity against APP. Without being bound to a particular theory, it is believed the activity of the hydantoins identified herein appears to be associated wi

HETEROCYCLIC FUSED PHENANTHROLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to heterocyclic fused phenanthrolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

Preparation of Triazolopyrimidines as Potential Antiasthma Agents

With the use of the human basophil histamine release assay, 5-aryl-2-aminotriazolopyrimidines were found to be active as mediator release inhibitors.These compounds were prepared by reacting arylamidines with sodium ethyl formylacetate or with ethyl propiolate to give pyrimidinones.Treatment with phosphorus oxychloride gave a chloropyrimidine, which was converted to a hydrazinopyrimidine with hydrazine.Cyclization, using cyanogen bromide, gave the triazolopyrimidines, after a Dimroth rearrangement.Following a structure-activity evaluation, the5--2-amino (8-10), 5-(3-bromophenyl)-2-amino (8-13), 5--2-amino (8-11), and 5-(4-pyridinyl)-2-amino (6-7) compounds were found to have the best activity.They were chosen for further pharmacological and toxicological study.

5-substituted[1,2,4]triazolo[1,5-c]pyrimidin-2-amines

This invention is concerned with 5-substituted[1,2,4]triazolo[1,5-c]pyrimidin-2-amines selected from those of Formula I, which are active as antiasthma agents.